| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.JHEP.2009.12.041 |
| P698 | PubMed publication ID | 20395009 |
| P50 | author | Ann-Lii Cheng | Q38639483 |
| P2093 | author name string | Fu-Chang Hu | |
| Li-Tzong Chen | |||
| Chiun Hsu | |||
| Ying-Chun Shen | |||
| Chia-Chi Cheng | |||
| P433 | issue | 6 | |
| P921 | main subject | meta-regression | Q6822263 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | 889-894 | |
| P577 | publication date | 2010-03-24 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach | |
| P478 | volume | 52 |
| Q38007308 | A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression |
| Q36934253 | A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma |
| Q38134777 | A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma |
| Q24607045 | ARID2: a new tumor suppressor gene in hepatocellular carcinoma |
| Q38066478 | Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis |
| Q34265805 | Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis |
| Q37972807 | Adjuvant therapy after curative treatment for hepatocellular carcinoma |
| Q36329125 | Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development |
| Q38100807 | Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials |
| Q41277166 | Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation |
| Q33904007 | Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study |
| Q92714242 | Chemoprevention of elite tea variety CFT-1 rich in EGCG against chemically induced liver cancer in rats |
| Q44998054 | Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers |
| Q42175640 | Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q36436294 | Current status of multimodal & combination therapy for hepatocellular carcinoma |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q55065395 | Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. |
| Q33742856 | Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma |
| Q45362610 | Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma |
| Q41430815 | Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study |
| Q34316969 | Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection |
| Q42092099 | FoxO3a nuclear localization and its association with β-catenin and Smads in IFN-α-treated hepatocellular carcinoma cell lines. |
| Q44734913 | Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression |
| Q37980015 | HCC: current surgical treatment concepts |
| Q40291586 | Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. |
| Q24315118 | Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma |
| Q45371119 | Hepatitis B virus DNA and hepatocellular carcinoma recurrence after resection: The lower, the better! |
| Q58021316 | Hepatocellular Carcinoma |
| Q29616359 | Hepatocellular carcinoma |
| Q34633249 | Hepatocellular carcinoma: insight from animal models |
| Q35567765 | Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. |
| Q26823395 | Liver resection and transplantation in hepatocellular carcinoma |
| Q34553534 | Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. |
| Q92666152 | Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma |
| Q28258769 | Management of HCC |
| Q35771842 | Management of Hepatocellular Carcinoma: Current Status and Future Directions |
| Q26799056 | Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma |
| Q36014255 | Management of hepatocellular carcinoma: an overview of major findings from meta-analyses |
| Q38059437 | Medical therapies for hepatocellular carcinoma: a critical view of the evidence |
| Q40904392 | Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. |
| Q41921421 | Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals |
| Q38112488 | Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma |
| Q38203306 | Postoperative therapy options for hepatocellular carcinoma |
| Q39674275 | Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma |
| Q37972806 | Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. |
| Q38070128 | Prevention of recurrence after curative treatment for hepatocellular carcinoma |
| Q38216004 | Prognostic factors for hepatocellular carcinoma recurrence |
| Q38864396 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment |
| Q38320467 | Recent advances in liver resection for hepatocellular carcinoma |
| Q26863748 | Recent advances in multidisciplinary management of hepatocellular carcinoma |
| Q38262115 | Recent advances in the surgical treatment of hepatocellular carcinoma |
| Q89966920 | Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection |
| Q94942876 | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
| Q40447188 | Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort. |
| Q37701106 | Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence |
| Q28066295 | Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function |
| Q38232812 | Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy |
| Q42272311 | Surgical outcomes and clinical characteristics of elderly patients undergoing curative hepatectomy for hepatocellular carcinoma |
| Q47098597 | Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data |
| Q30250096 | The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma |
| Q36322143 | Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy |
| Q87421151 | [National S3 guidelines on hepatocellular carcinoma] |
Search more.